LTC1793824I2 - Naujos farmacinės kompozicijos, apimančios 4-(4-(3-(4-chlor-3-trifluormetilfenil)ureido)-3-fluorfenoksi)piridin-2-karboksirūgštį, hiperproliferacinių sutrikimų gydymui - Google Patents

Naujos farmacinės kompozicijos, apimančios 4-(4-(3-(4-chlor-3-trifluormetilfenil)ureido)-3-fluorfenoksi)piridin-2-karboksirūgštį, hiperproliferacinių sutrikimų gydymui

Info

Publication number: LTC1793824I2
Authority: LT; Lithuania
Prior art keywords: fluorophenoxy; trifluoromethylphenyl; ureido; pyridine; chloro
Prior art date: 2004-08-27

Application number

LTPA2016008C

Other languages

English (en)

Original Assignee

Bayer Healthcare Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-08-27

Filing date

2016-03-22

Publication date

2017-06-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35517032&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC1793824(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-03-22 Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc

2017-06-12 Publication of LTC1793824I2 publication Critical patent/LTC1793824I2/lt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nutrition Science (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Physiology (AREA)
Oncology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Pyridine Compounds (AREA)
Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)

LTPA2016008C 2004-08-27 2016-03-22 Naujos farmacinės kompozicijos, apimančios 4-(4-(3-(4-chlor-3-trifluormetilfenil)ureido)-3-fluorfenoksi)piridin-2-karboksirūgštį, hiperproliferacinių sutrikimų gydymui LTC1793824I2 (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US60475204P	2004-08-27	2004-08-27
PCT/US2005/030541 WO2006026500A1 (en)	2004-08-27	2005-08-29	New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carboxylic acid for the treatment of hyper-proliferative disorders

Publications (1)

Publication Number	Publication Date
LTC1793824I2 true LTC1793824I2 (lt)	2017-06-12

Family

ID=35517032

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTPA2016008C LTC1793824I2 (lt)	2004-08-27	2016-03-22	Naujos farmacinės kompozicijos, apimančios 4-(4-(3-(4-chlor-3-trifluormetilfenil)ureido)-3-fluorfenoksi)piridin-2-karboksirūgštį, hiperproliferacinių sutrikimų gydymui

Country Status (41)

Country	Link
US (2)	US20060058358A1 (lt)
EP (2)	EP2589384A1 (lt)
JP (1)	JP5017115B2 (lt)
KR (1)	KR101336737B1 (lt)
CN (2)	CN101287463A (lt)
AR (1)	AR050616A1 (lt)
AU (1)	AU2005279996A1 (lt)
BR (1)	BRPI0514715B1 (lt)
CA (1)	CA2578438C (lt)
CL (1)	CL2010001484A1 (lt)
CR (1)	CR8980A (lt)
CY (1)	CY2017038I1 (lt)
DK (1)	DK1793824T3 (lt)
EA (1)	EA010832B1 (lt)
EC (1)	ECSP077299A (lt)
ES (1)	ES2561618T3 (lt)
GT (1)	GT200500230A (lt)
HN (1)	HN2005000484A (lt)
HR (1)	HRP20160156T1 (lt)
HU (2)	HUE026654T2 (lt)
IL (1)	IL181590A (lt)
LT (1)	LTC1793824I2 (lt)
LU (1)	LUC00047I2 (lt)
MA (1)	MA28911B1 (lt)
ME (2)	MEP35808A (lt)
MX (1)	MX2007002397A (lt)
MY (1)	MY191349A (lt)
NI (1)	NI200700064A (lt)
NO (2)	NO343937B1 (lt)
NZ (1)	NZ553557A (lt)
PE (2)	PE20100432A1 (lt)
PL (1)	PL1793824T3 (lt)
PT (1)	PT1793824E (lt)
RS (1)	RS54580B1 (lt)
SI (1)	SI1793824T1 (lt)
TN (1)	TNSN07076A1 (lt)
TW (1)	TWI369987B (lt)
UA (1)	UA92472C2 (lt)
UY (1)	UY29086A1 (lt)
WO (1)	WO2006026500A1 (lt)
ZA (1)	ZA200702392B (lt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002534468A (ja) *	1999-01-13	2002-10-15	バイエルコーポレイション	ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
US8124630B2 (en)	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) *	2001-04-20	2008-05-13	Bayer Pharmaceuticals Corporation	Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
US20080108672A1 (en) *	2002-01-11	2008-05-08	Bernd Riedl	Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
PT1478358E (pt)	2002-02-11	2013-09-11	Bayer Healthcare Llc	Tosilato de sorafenib para o tratamento de doenças caracterizadas por angiogénese anormal
US7557129B2 (en) *	2003-02-28	2009-07-07	Bayer Healthcare Llc	Cyanopyridine derivatives useful in the treatment of cancer and other disorders
PL1626714T3 (pl) *	2003-05-20	2007-12-31	Bayer Healthcare Llc	Diarylowe pochodne mocznika do schorzeń, w których pośredniczy PDGFR
CN102816113B (zh) *	2003-07-23	2015-05-13	拜耳医药保健有限责任公司	用于治疗和预防疾病和疾病症状的氟代ω-羧芳基二苯基脲
EP1797038B1 (en) *	2004-09-29	2012-06-13	Bayer Pharma Aktiengesellschaft	Thermodynamically stable form of bay 43-9006 tosylate
DE602006017188D1 (de) *	2005-03-07	2010-11-11	Bayer Schering Pharma Ag	Pharmazeutische zusammensetzung mit einem omega-carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs
US8119655B2 (en)	2005-10-07	2012-02-21	Takeda Pharmaceutical Company Limited	Kinase inhibitors
US20080026038A1 (en) *	2006-07-26	2008-01-31	Remington Direct Lp	No laxation, low flatulence bulking system
US20090074917A2 (en) *	2006-07-26	2009-03-19	Remington Direct Lp	Low-calorie, no laxation bulking system
BRPI0719883A2 (pt)	2006-10-09	2015-05-05	Takeda Pharmaceutical	Inibidores de quinase
AR062927A1 (es) *	2006-10-11	2008-12-17	Bayer Healthcare Ag	4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
EP1920767A1 (en) *	2006-11-09	2008-05-14	Abbott GmbH & Co. KG	Melt-processed imatinib dosage form
JP2010509289A (ja) *	2006-11-09	2010-03-25	アボットゲーエムベーハーウントコンパニーカーゲー	チロシンキナーゼ阻害剤の経口投与用薬学的剤形
AR065720A1 (es)	2007-03-14	2009-06-24	Tibotec Pharm Ltd	Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
CA2686756A1 (en) *	2007-05-11	2008-11-20	F. Hoffmann-La Roche Ag	Pharmaceutical compositions for poorly soluble drugs
WO2009114703A2 (en) *	2008-03-12	2009-09-17	Fox Chase Cancer Center	Combination therapy for the treatment of cancer
UA107186C2 (xx) *	2008-12-03	2014-12-10		Тверді форми дозування бендамустину
WO2010068951A1 (en) *	2008-12-12	2010-06-17	Fox Chase Cancer Center	Combination therapy based on src and aurora kinase inhibition for the treatment of cancer
JO3112B1 (ar) *	2010-03-29	2017-09-20	Ferring Bv	تركيبة دوائية سريعة التحلل
AR081060A1 (es)	2010-04-15	2012-06-06	Bayer Schering Pharma Ag	Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
MX2012014387A (es) *	2010-06-09	2013-05-01	Abbvie Inc	Dispersiones solidas que contienen inhibidores de cinasa.
SG10201505484RA (en)	2010-07-12	2015-09-29	Salix Pharmaceuticals Ltd	Formulations of rifaximin and uses thereof
JP2013531067A (ja)	2010-07-19	2013-08-01	バイエルヘルスケアリミティドライアビリティカンパニー	疾病及び状態の処置及び予防のためのフルオロ置換オメガ−カルボキシアリールジフェニル尿素を用いた組み合わせ薬
UA112163C2 (uk)	2010-10-01	2016-08-10	Байєр Інтеллектуал Проперті Гмбх	Комбінації, які містять заміщений n-(2-ариламіно)арилсульфонамід
CA3152557A1 (en)	2010-10-29	2012-05-03	Abbvie Inc.	Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) *	2010-10-29	2017-02-10		Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CN103301066B (zh) *	2012-03-15	2018-12-07	苏州泽璟生物制药有限公司	一种改善吸收性能的固体分散体及其制备
JO3479B1 (ar)	2012-09-06	2020-07-05	Bayer Healthcare Llc	تركيبة دوائية مغلفة تحتوي على ريجورافنيب
US9211290B2 (en) *	2012-12-31	2015-12-15	Noven Therapeutics, Llc	Solid dispersions of amorphous paroxetine mesylate
IN2013CH04511A (lt)	2013-10-04	2015-04-10	Hetero Research Foundation
CN104721142B (zh) *	2013-12-18	2020-04-28	山东新时代药业有限公司	一种利伐沙班固体分散体及其制备方法
WO2016005874A1 (en) *	2014-07-09	2016-01-14	Shilpa Medicare Limited	Process for the preparation of regorafenib and its crystalline forms
CN105267167A (zh) *	2015-09-11	2016-01-27	江苏嘉逸医药有限公司	一种瑞戈非尼口服固体药物组合物的制备方法
CN105330600B (zh) *	2015-11-30	2018-05-22	山东罗欣药业集团股份有限公司	一种瑞戈菲尼的制备方法
CN105879049B (zh) *	2016-05-13	2019-03-26	浙江大学	一种瑞戈非尼与β-环糊精的包合物及其制备方法
CN107661296A (zh) *	2016-07-27	2018-02-06	江苏先声药业有限公司	一种瑞戈非尼固体分散体及其制备方法
RS63751B1 (sr)	2016-09-30	2022-12-30	Salix Pharmaceuticals Inc	Čvrsti disperzioni oblici rifaksimina
CN111166724A (zh) *	2018-11-09	2020-05-19	北京化工大学	一种瑞戈非尼纳米分散体、片剂及其制备方法
EP3861989A1 (en)	2020-02-07	2021-08-11	Bayer Aktiengesellschaft	Pharmaceutical composition containing regorafenib and a stabilizing agent
CA3170261A1 (en) *	2020-03-05	2021-09-10	Frederic Dargelas	Pharmaceutical compositions of a kinase inhibitor
CN112587485A (zh) *	2021-01-08	2021-04-02	湖南南新制药股份有限公司	一种药物固体分散体及其制备方法
CN112842998A (zh) *	2021-01-19	2021-05-28	深圳市简一生物科技有限公司	一种瑞戈非尼分散剂及其制备方法
FR3123358B1 (fr)	2021-05-25	2024-05-10	Vecormat Bfc	Procédé d’élaboration d’un matériau naturel composite à faible emprunte carbone et fort taux de matière naturelle.
WO2022253945A1 (en)	2021-06-04	2022-12-08	Bayer Aktiengesellschaft	Pharmaceutical dosage forms comprising 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}-benzamide
CN114767633B (zh) *	2022-04-07	2023-03-31	郑州大学第一附属医院	含抗乳腺癌药物他莫昔芬的固体分散体、制备方法及制剂
WO2025242583A1 (en)	2024-05-24	2025-11-27	Bayer Consumer Care Ag	Novel formulation comprising elinzanetant in a solid dispersion

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4151273A (en) *	1974-10-31	1979-04-24	The Regents Of The University Of California	Increasing the absorption rate of insoluble drugs
US4220302A (en)	1978-07-21	1980-09-02	Hampton Diane M	Nursing bottle holder
CA2108575C (en) *	1991-04-16	2002-10-22	Kouichi Nakamichi	Method of manufacturing solid dispersion
KR100622138B1 (ko) *	1997-12-22	2006-09-13	바이엘 코포레이션	아릴 및 헤테로아릴 치환 헤테로고리형 우레아를 사용한라프 키나제의 저해
CZ299156B6 (cs) *	1997-12-22	2008-05-07	Bayer Corporation	Substituované heterocyklické mocoviny, farmaceutické prípravky je obsahující a jejich použití
PL195808B1 (pl) *	1997-12-22	2007-10-31	Bayer Corp	Moczniki arylowe, kompozycja je zawierająca i ichzastosowanie
US7928239B2 (en)	1999-01-13	2011-04-19	Bayer Healthcare Llc	Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
RS51497B (sr) *	1999-01-13	2011-04-30	Bayer Healthcare Llc	w-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
JP2002534468A (ja) *	1999-01-13	2002-10-15	バイエルコーポレイション	ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
EP1140840B1 (en)	1999-01-13	2006-03-22	Bayer Pharmaceuticals Corp.	-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP3789066B2 (ja)	1999-12-08	2006-06-21	三菱電機株式会社	液晶表示装置
WO2001078716A1 (en) *	2000-04-19	2001-10-25	Fujisawa Pharmaceutical Co., Ltd.	Solid dispersion with improved absorbability
US8725620B2 (en)	2000-07-10	2014-05-13	Nobuyoshi Morimoto	System and method for negotiating improved terms for products and services being purchased through the internet
CA2418490A1 (en) *	2000-08-11	2002-02-21	Eisai Co., Ltd.	Drug-containing solid dispersion having improved solubility
US20040058956A1 (en)	2000-12-11	2004-03-25	Yohko Akiyama	Pharmaceutical composition having an improved water solubility
US7235576B1 (en) *	2001-01-12	2007-06-26	Bayer Pharmaceuticals Corporation	Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
PT1368006E (pt) *	2001-02-13	2006-08-31	Astrazeneca Ab	Nova formulacao de libertacao modificada
SE0103838D0 (sv) *	2001-11-16	2001-11-16	Astrazeneca Ab	Pharmaceutical formulation & product
CA2466762A1 (en) *	2001-12-04	2003-06-12	Onyx Pharmaceuticals, Inc.	Raf-mek-erk pathway inhibitors to treat cancer
US20030207872A1 (en) *	2002-01-11	2003-11-06	Bayer Corporation	Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
PL373914A1 (en) *	2002-02-01	2005-09-19	Pfizer Products Inc.	Immediate release dosage forms containing solid drug dispersions
PT1478358E (pt) *	2002-02-11	2013-09-11	Bayer Healthcare Llc	Tosilato de sorafenib para o tratamento de doenças caracterizadas por angiogénese anormal
CA2430180C (en)	2003-05-21	2010-03-16	Royal Group Technologies Limited	Cascade shade
CN102816113B (zh)	2003-07-23	2015-05-13	拜耳医药保健有限责任公司	用于治疗和预防疾病和疾病症状的氟代ω-羧芳基二苯基脲
JP5128948B2 (ja) *	2004-08-27	2013-01-23	ニッポネックスインコーポレイテッド	癌の治療のための新規な薬剤組成物

2005
- 2005-08-25 MY MYPI20054000A patent/MY191349A/en unknown
- 2005-08-26 AR ARP050103568A patent/AR050616A1/es not_active Application Discontinuation
- 2005-08-26 GT GT200500230A patent/GT200500230A/es unknown
- 2005-08-26 US US11/212,109 patent/US20060058358A1/en not_active Abandoned
- 2005-08-26 HN HN2005000484A patent/HN2005000484A/es unknown
- 2005-08-26 PE PE2010000029A patent/PE20100432A1/es active IP Right Grant
- 2005-08-26 PE PE2005000984A patent/PE20060505A1/es active IP Right Grant
- 2005-08-26 TW TW094129395A patent/TWI369987B/zh not_active IP Right Cessation
- 2005-08-26 UY UY29086A patent/UY29086A1/es not_active Application Discontinuation
- 2005-08-29 PT PT57924862T patent/PT1793824E/pt unknown
- 2005-08-29 MX MX2007002397A patent/MX2007002397A/es active IP Right Grant
- 2005-08-29 ES ES05792486.2T patent/ES2561618T3/es not_active Expired - Lifetime
- 2005-08-29 NZ NZ553557A patent/NZ553557A/en not_active IP Right Cessation
- 2005-08-29 ME MEP-358/08A patent/MEP35808A/xx unknown
- 2005-08-29 JP JP2007533489A patent/JP5017115B2/ja not_active Expired - Lifetime
- 2005-08-29 EP EP13151040.6A patent/EP2589384A1/en not_active Withdrawn
- 2005-08-29 CN CNA2005800371513A patent/CN101287463A/zh active Pending
- 2005-08-29 PL PL05792486T patent/PL1793824T3/pl unknown
- 2005-08-29 BR BRPI0514715-8A patent/BRPI0514715B1/pt active IP Right Grant
- 2005-08-29 AU AU2005279996A patent/AU2005279996A1/en not_active Abandoned
- 2005-08-29 KR KR1020077006801A patent/KR101336737B1/ko not_active Expired - Lifetime
- 2005-08-29 DK DK05792486.2T patent/DK1793824T3/en active
- 2005-08-29 UA UAA200703203A patent/UA92472C2/ru unknown
- 2005-08-29 RS RS20160039A patent/RS54580B1/sr unknown
- 2005-08-29 CN CN2012102807209A patent/CN102885813A/zh active Pending
- 2005-08-29 WO PCT/US2005/030541 patent/WO2006026500A1/en not_active Ceased
- 2005-08-29 HR HRP20160156TT patent/HRP20160156T1/hr unknown
- 2005-08-29 CA CA2578438A patent/CA2578438C/en not_active Expired - Lifetime
- 2005-08-29 HU HUE05792486A patent/HUE026654T2/en unknown
- 2005-08-29 EA EA200700501A patent/EA010832B1/ru unknown
- 2005-08-29 SI SI200532037T patent/SI1793824T1/sl unknown
- 2005-08-29 ME MEP-2008-358A patent/ME00152B/me unknown
- 2005-08-29 EP EP05792486.2A patent/EP1793824B1/en not_active Revoked
2007
- 2007-02-26 TN TNP2007000076A patent/TNSN07076A1/en unknown
- 2007-02-27 NI NI200700064A patent/NI200700064A/es unknown
- 2007-02-27 IL IL181590A patent/IL181590A/en active IP Right Grant
- 2007-03-05 EC EC2007007299A patent/ECSP077299A/es unknown
- 2007-03-07 CR CR8980A patent/CR8980A/es unknown
- 2007-03-22 ZA ZA200702392A patent/ZA200702392B/xx unknown
- 2007-03-22 MA MA29767A patent/MA28911B1/fr unknown
- 2007-03-26 NO NO20071584A patent/NO343937B1/no active Protection Beyond IP Right Term
2010
- 2010-12-20 CL CL2010001484A patent/CL2010001484A1/es unknown
2016
- 2016-03-22 LT LTPA2016008C patent/LTC1793824I2/lt unknown
2017
- 2017-01-27 US US15/417,469 patent/US20170165243A1/en not_active Abandoned
- 2017-11-08 LU LU00047C patent/LUC00047I2/fr unknown
- 2017-11-09 CY CY2017038C patent/CY2017038I1/el unknown
- 2017-11-21 HU HUS1700047C patent/HUS1700047I1/hu unknown
2019
- 2019-08-05 NO NO2019033C patent/NO2019033I1/no unknown

Also Published As

Publication number	Publication date
BRPI0514715A (pt)	2008-06-24
CN102885813A (zh)	2013-01-23
CL2010001484A1 (es)	2011-04-25
SI1793824T1 (sl)	2016-03-31
US20060058358A1 (en)	2006-03-16
ZA200702392B (en)	2008-11-26
RS54580B1 (sr)	2016-06-30
EA200700501A1 (ru)	2007-08-31
KR101336737B1 (ko)	2013-12-04
AU2005279996A1 (en)	2006-03-09
TWI369987B (en)	2012-08-11
NI200700064A (es)	2008-03-03
LUC00047I1 (lt)	2017-11-15
PL1793824T3 (pl)	2016-06-30
TW200616627A (en)	2006-06-01
NO20071584L (no)	2007-05-24
HN2005000484A (es)	2010-06-08
MX2007002397A (es)	2007-05-15
CN101287463A (zh)	2008-10-15
PT1793824E (pt)	2016-03-11
CA2578438C (en)	2015-10-06
PE20100432A1 (es)	2010-07-21
MY191349A (en)	2022-06-17
BRPI0514715B1 (pt)	2021-11-03
MA28911B1 (fr)	2007-10-01
EA010832B1 (ru)	2008-12-30
PE20060505A1 (es)	2006-06-18
HRP20160156T1 (hr)	2016-03-11
GT200500230A (es)	2006-03-28
EP1793824A1 (en)	2007-06-13
CY2017038I2 (el)	2018-06-27
HUS1700047I1 (hu)	2017-12-28
CR8980A (es)	2007-10-22
WO2006026500A1 (en)	2006-03-09
ES2561618T3 (es)	2016-02-29
UY29086A1 (es)	2006-03-31
NZ553557A (en)	2010-08-27
TNSN07076A1 (en)	2008-06-02
JP5017115B2 (ja)	2012-09-05
ECSP077299A (es)	2007-04-26
CA2578438A1 (en)	2006-03-09
NO343937B1 (no)	2019-07-15
LUC00047I2 (lt)	2018-01-10
UA92472C2 (ru)	2010-11-10
IL181590A (en)	2013-04-30
ME00152B (me)	2010-10-10
EP2589384A1 (en)	2013-05-08
CY2017038I1 (el)	2018-06-27
US20170165243A1 (en)	2017-06-15
MEP35808A (en)	2010-06-10
NO2019033I1 (no)	2019-08-05
DK1793824T3 (en)	2016-02-01
JP2008511685A (ja)	2008-04-17
EP1793824B1 (en)	2015-11-18
KR20070067104A (ko)	2007-06-27
HUE026654T2 (en)	2016-07-28
IL181590A0 (en)	2007-07-04
AR050616A1 (es)	2006-11-08

Publication	Publication Date	Title
LTC1793824I2 (lt)	2017-06-12	Naujos farmacinės kompozicijos, apimančios 4-(4-(3-(4-chlor-3-trifluormetilfenil)ureido)-3-fluorfenoksi)piridin-2-karboksirūgštį, hiperproliferacinių sutrikimų gydymui
JO3021B1 (ar)	2016-09-05	احادي هيدرات 4-[ 4-{[4- كلورو - 3- (ثلاثي فلورو ميثيل) فينيل ] كربامويل} امينو] -3- فلورو فينوكسي] -n- ميثيل بيريدين -2- كربوكساميد
LTC1781298I2 (lt)	2018-09-25	Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
ITMI20020756A1 (it)	2003-10-09	Composizioni farmaceutiche topiche per il trattamento delle dermatiti
WO2006120682A3 (en)	2007-01-25	Compositions and methods for treating hyperproliferative epidermal diseases
NO20035496D0 (no)	2003-12-10	Substituerte sulfonamidforbindelser, fremgangsmåte for deres anvendelse sommedikament til behandling av CNS-forstyrrelser, overvekt og typeII-diabetes
EA201070699A1 (ru)	2011-02-28	Композиции 3-(6-(1-2,2-дифторбензо[d][1,3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
LTC1562603I2 (lt)	2016-12-12	Nauji vaistai, skirti lėtinių obstrukcinių plaučių ligų gydymui
NO20064041L (no)	2006-09-08	Substituerte pyrazolin sammensetninger, deres fremstilling og anvendelse som medikamenter
NO20081482L (no)	2008-05-16	Delta- og epsilon-krystallformer for imatinibmesylat
NO343929B3 (no)	2019-07-08	1-[2-(2,4-dimetylfenylsulfanyl-fenyl]-piperazin som en forbindelse med kombinert serotoninreopptak, 5-HT3- og 5HT1A-aktivitet for behandlingen av kognitiv smerte
IL205624A (en)	2016-10-31	Carboxamide, Sulfonamide and Amine Compounds, Their Pharmaceutical Preparations
IL182763A (en)	2010-12-30	Indol-3-ylidene-hydrazino-biphenyl- carboxylic acid derivatives and pharmaceutical compositions comprising them for modulating thrombopoietin activity
JP2007506758A5 (ja)	2007-10-18	４−（１−ベンゾフラン−３−イル−メチリデンアミノオキシ−プロポキシ）−安息香酸誘導体および線溶系の障害、血栓症の治療用のｐａｉ−１阻害剤としての関連化合物
IL179611A (en)	2013-05-30	History 1-Aza-bicycloalkyl, their process, their pharmaceutical preparations and their use in the preparation of drugs for the treatment of psychotic disorders
MA28706B1 (fr)	2007-06-01	Antagoniste des recepteurs du glucagon, preparation et utilisations therapeutiques
NO20064078L (no)	2006-09-11	Substituerte azetidinsammensetninger, deres fremstilling og anvendelse som medikamenter
WO2005086656A3 (en)	2005-12-29	Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
DK1614419T3 (da)	2012-11-19	Midler til forebyggelse/behandling af retinale nervesygdomme, indeholdende alkyletherderivater eller salte deraf
ITFI20050041A1 (it)	2006-09-16	Idrossammati come inibitori dell'istone deacelitasi, loro preparazione e formulazioni farmaceutiche che li contengono
DK1666473T3 (da)	2013-03-25	Carboxylsyreforbindelser og medicinske sammensætninger indeholdende samme som aktiv ingrediens
FR2911278B1 (fr)	2009-05-01	Procede d'obtention d'un actif cosmetique depigmentant, principe actif obtenu et compositions l'incluant
WO2005112923A3 (en)	2006-09-14	5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
PL376713A1 (pl)	2006-01-09	Zastosowanie pochodnych kwasu piperazynosulfonowego jako antagonistów CCR1 do leczenia zwłóknienia, choroby Alzheimera i innych zaburzeń
CL2004001458A1 (es)	2005-05-20	Compuestos derivados de 3-(guanidinocarbonil) heterociclos, composicion farmaceutica, procedimiento de preparacion, utiles para preparar un medicamento para tratar trastornos fibroticos de higado, rinon, de organos internos, trastornos inflamatorios,